This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Funds See Value in Lagging Sector

NEW YORK ( TheStreet) -- At a time when stocks have been climbing nicely, health care and drug shares have lagged. During the past 12 months, health funds returned 10.5%, trailing the S&P 500 by 10 percentage points, according to Morningstar.

A variety of factors have held back companies in the sector. Responding to the debt crisis, European national health plans hurt drug companies by demanding price cuts. In the U.S., many drug and device companies announced that their earnings would suffer because of health care reform. That was a special blow for pharmaceutical blue-chips that have long been plagued by concerns about patent expirations.

Although the industry will continue to face headwinds, some health fund managers argue that the stocks now represent compelling values. The portfolios of health funds now have price-to-earnings ratios of 14. That is below the P/E of the S&P 500. Blue-chips such as Merck (MRK) and Eli Lilly (LLY) trade at forward P/Es of less than 9. In the past, health stocks typically traded at a premium to the market. "After going through a period of underperformance, the health care stocks are universally cheap," says Erin Xie, portfolio manager of BlackRock Health Sciences Opportunities (SHSAX).

Managers at fund company T. Rowe Price (TROW) say that health care reform will hurt some stocks but that not all businesses will suffer. In many cases, the market has over-reacted to the bad news, T. Rowe Price argues.

Shortly after the legislation passed in March 2010, some companies announced that their earnings for the year would be 2% to 5% lower than analysts expected. That surprised investors and sent the stocks lower. This year companies are reporting additional costs.

Morningstar pharmaceutical analyst Damien Conover estimates that health care reform will cost the drug industry $100 billion in the next decade. Under the legislation, health companies will have to pay $28 billion in fees to support the drug programs of Medicare and Medicaid. Drug companies also will have to rebate Medicaid $2 billion annually. In addition, the industry is required to spend $35 billion to subsidize patients who face the "doughnut hole," bills that are not covered by Medicare Part D.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.63 -0.65%
FB $119.18 1.20%
GOOG $710.19 1.20%
TSLA $214.78 1.50%
YHOO $37.24 0.81%


Chart of I:DJI
DOW 17,728.75 +68.04 0.39%
S&P 500 2,055.44 +4.81 0.23%
NASDAQ 4,727.7440 +10.65 0.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs